194 related articles for article (PubMed ID: 28240588)
1. Measurement of antinuclear antibodies and their fine specificities: time for a change in strategy?
Otten HG; Brummelhuis WJ; Fritsch-Stork R; Leavis HL; Wisse BW; van Laar JM; Derksen RHWM
Clin Exp Rheumatol; 2017; 35(3):462-470. PubMed ID: 28240588
[TBL] [Abstract][Full Text] [Related]
2. Clinical use of anti-DFS70 autoantibodies.
Kang SY; Lee WI; Kim MH; La Jeon Y
Rheumatol Int; 2019 Aug; 39(8):1423-1429. PubMed ID: 30972541
[TBL] [Abstract][Full Text] [Related]
3. Cost-effective detection of non-antidouble-stranded DNA antinuclear antibody specificities in daily clinical practice.
Vos PA; Bast EJ; Derksen RH
Rheumatology (Oxford); 2006 May; 45(5):629-35. PubMed ID: 16368728
[TBL] [Abstract][Full Text] [Related]
4. [Prevalence and diagnostic value of antinuclear antibodies without identified antigenic target: a retrospective study of 90 patients].
Feki S; Frikha F; Ben Hadj Hmida Y; Abed S; Ben Ayed M; Turki H; Hachicha J; Baklouti S; Bahloul Z; Masmoudi H
Rev Med Interne; 2012 Sep; 33(9):475-81. PubMed ID: 22658165
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the LIAISON ANA screen assay for antinuclear antibody testing in autoimmune diseases.
Ghillani P; Rouquette AM; Desgruelles C; Hauguel N; Le Pendeven C; Piette JC; Musset L
Ann N Y Acad Sci; 2007 Aug; 1109():407-13. PubMed ID: 17785329
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the analytical and clinical performances of two different routine testing protocols for antinuclear antibody screening.
González Rodríguez C; Fuentes Cantero S; Pérez Pérez A; Vázquez Barbero FJ; León Justel A
J Clin Lab Anal; 2021 Sep; 35(9):e23914. PubMed ID: 34347308
[TBL] [Abstract][Full Text] [Related]
7. [Antinucleolar antibodies in diagnostics of antiphospholipid syndrome].
Zabek J; Palacz A; Pyka J; Krzewska I
Pol Arch Med Wewn; 2008; 118 Suppl():25-30. PubMed ID: 19562966
[TBL] [Abstract][Full Text] [Related]
8. Detection of antinuclear antibodies by indirect immunofluorescence and by solid phase assay.
Op De Beeck K; Vermeersch P; Verschueren P; Westhovens R; Mariën G; Blockmans D; Bossuyt X
Autoimmun Rev; 2011 Oct; 10(12):801-8. PubMed ID: 21741497
[TBL] [Abstract][Full Text] [Related]
9. The clinical significance of borderline results of the Elia CTD Screen assay.
Robier C; Amouzadeh-Ghadikolai O
Clin Chem Lab Med; 2018 Nov; 56(12):2088-2092. PubMed ID: 30032128
[TBL] [Abstract][Full Text] [Related]
10. The antinuclear antibody dense fine speckled pattern and possible clinical associations: An indication of a proinflammatory microenvironment.
Lundgren MC; Sapkota S; Peterson DJ; Crosson JT
J Immunol Methods; 2021 Jan; 488():112904. PubMed ID: 33121975
[TBL] [Abstract][Full Text] [Related]
11. [Performance and clinical evaluation of antinuclear antibody test based on fluorescence enzyme immunoassay].
Watanabe N; Nagatomo R; Okubo S; Yokota H; Ikeda H; Yatomi Y
Rinsho Byori; 2014 Apr; 62(4):315-23. PubMed ID: 25022060
[TBL] [Abstract][Full Text] [Related]
12. [Clinical significance of determination of DFS70 antibodies to rule out connective tissue diseases].
Kiefer D; von Brunn M; Baraliakos X; Andreica I; Braun J
Z Rheumatol; 2020 Oct; 79(8):749-754. PubMed ID: 31889213
[TBL] [Abstract][Full Text] [Related]
13. Performance of antinuclear antibody connective tissue disease screen.
López-Hoyos M; Rodríguez-Valverde V; Martinez-Taboada V
Ann N Y Acad Sci; 2007 Aug; 1109():322-9. PubMed ID: 17785321
[TBL] [Abstract][Full Text] [Related]
14. Autoantibodies to dense-fine-speckled 70 (DFS70) do not necessarily rule out connective tissue diseases.
Mockenhaupt LM; Dolscheid-Pommerich R; Stoffel-Wagner B; Behning C; Brossart P; Schäfer VS
Semin Arthritis Rheum; 2022 Feb; 52():151936. PubMed ID: 35027246
[TBL] [Abstract][Full Text] [Related]
15. The clinical relevance of antinuclear antibodies in connective tissue diseases.
Bombardieri S; Neri R; Tartarelli G; d'Ascanio A; Giovanelli L
Scand J Rheumatol Suppl; 1987; 66():35-45. PubMed ID: 3502510
[TBL] [Abstract][Full Text] [Related]
16. Detection and identification of antinuclear antibodies (ANA) in a large and consecutive cohort of serum samples referred for ANA testing.
Peene I; Meheus L; Veys EM; De Keyser F
Ann Rheum Dis; 2001 Dec; 60(12):1131-6. PubMed ID: 11709455
[TBL] [Abstract][Full Text] [Related]
17. Undifferentiated connective tissue disease: predictors of evolution into definite disease.
García-González M; Rodríguez-Lozano B; Bustabad S; Ferraz-Amaro I
Clin Exp Rheumatol; 2017; 35(5):739-745. PubMed ID: 28770704
[TBL] [Abstract][Full Text] [Related]
18. [Detection of anti-SSA/Ro antibody by ELISA, double immunodiffusion, and immunoblotting: a comparative study].
Tong SQ; Shi Q; Wen XH; Gan XD; Shi YP; Zhao Y; Zeng XF; Zhang FC; Dong Y
Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(35):2455-7. PubMed ID: 17156670
[TBL] [Abstract][Full Text] [Related]
19. Laboratory screening of connective tissue diseases by a new automated ENA screening assay (EliA Symphony) in clinically defined patients.
González C; García-Berrocal B; Pérez M; Navajo JA; Herraez O; González-Buitrago JM
Clin Chim Acta; 2005 Sep; 359(1-2):109-14. PubMed ID: 15894301
[TBL] [Abstract][Full Text] [Related]
20. From ANA to ENA: how to proceed?
Damoiseaux JG; Tervaert JW
Autoimmun Rev; 2006 Jan; 5(1):10-7. PubMed ID: 16338206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
